This report was first published by Endpoints News. To see the original version, click here
## FRIDAY 11/14 9am ET PUB ##
Paul Berns was in the middle of a haircut when his phone rang. A month earlier, he had helped steer the biotech he co-founded, Metsera, to a $7.3 billion deal with Pfizer. With the deal signed, Metsera was now focused on planning to integrate with the giant New York drugmaker, and Berns was thinking about what he would do after.
您已閱讀5%（450字），剩余95%（8258字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。